Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients-Reference-Cited by-同舟云学术

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients

Published:2018-05-06 Issue:7 Volume:84 Page:1587-1597
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Lin Xiao-bin¹²³,Li Zi-wei¹²⁴,Yan Miao¹²^ORCID,Zhang Bi-kui¹²,Liang Wu⁵,Wang Feng¹²,Xu Ping¹²,Xiang Da-xiong¹²,Xie Xu-biao⁶,Yu Shao-jie⁶,Lan Gong-bin⁶,Peng Feng-hua⁶

Affiliation:

1. Department of Pharmacy, the Second Xiangya Hospital; Central South University; Changsha Hunan 410011 China

2. Institute of Clinical Pharmacy; Central South University; Changsha Hunan 410011 China

3. Department of Pharmacy; the First Affiliated Hospital of Sun Yat-sen University; Guangzhou Guangdong 510080 China

4. Department of Pharmacy; Ruijin Hospital Shanghai Jiaotong University School of Medicine; Shanghai 200025 China

5. Beijing Dryas Pharma-Tech Co. LTD.; Beijing 100085 China

6. Department of Urological Organ Transplantation, the Second Xiangya Hospital; Central South University; Changsha Hunan 410011 China

Funder

The Project of New Clinic Techniques of Central South University, China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13595/fullpdf

Reference43 articles.

1. Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study;Lopez-Medrano;Am J Transplant,2016

2. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America;Patterson;Clin Infect Dis,2016

3. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America;Pappas;Clin Infect Dis,2016

4. Adverse effects of voriconazole: over a decade of use;Levine;Clin Transplant,2016

5. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections;Lamoureux;Int J Antimicrob Agents,2016

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug–Drug Interaction Between Voriconazole and Flucloxacillin;European Journal of Drug Metabolism and Pharmacokinetics;2024-09-14

2. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis;Frontiers in Pharmacology;2024-08-20

3. Renal Replacement Therapy as a New Indicator of Voriconazole Clearance in a Population Pharmacokinetic Analysis of Critically Ill Patients;Pharmaceuticals;2024-05-22

4. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients;Pharmacogenetics and Genomics;2024-05-15

5. Population Pharmacokinetics of Voriconazole and Dose Optimization in Elderly Chinese Patients;The Journal of Clinical Pharmacology;2023-10-16